The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
Non-metastatic castration-resistant prostate cancer (nmCRPC) is a heterogeneous disease with variable potential in developing into overt metastases. It is an area of increased unmet need in advanced prostate cancer and for which there had been no great treatments until recent US Food and Drug Admini...
Main Authors: | Joelle El-Amm, Jeanny B Aragon-Ching |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-02-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.1177/1179554919833927 |
Similar Items
-
Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
by: Giuseppe Fallara, et al.
Published: (2023-06-01) -
HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01) -
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
by: Wout Devlies, et al.
Published: (2020-11-01) -
ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment
by: Jeanny B Aragon-Ching
Published: (2023-01-01) -
Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
by: Meagher MF, et al.
Published: (2023-11-01)